JAYKAYNSEJaykay Enterprises LimitedMediumNeutral
Announced Thu, 28 May · 18:29 IST

Corrigendum to the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026

Qualified OpinionEmphasis Of MatterExceptional ItemGoing ConcernResults View source PDF

JAYKAY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-20.7%1-day move
₹213.48
prior close
₹205.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-4.9-8.1-7.5-8.6-20.7-16.7-14.3-15.2-15.7-15.4-13.8-19.4
Up moveDown movePending
AI summary

Jaykay Enterprises filed a corrigendum correcting typographical errors in its FY2026 audited results. Key corrections include Other Income revised from Rs. 210.73 lakh to Rs. 242.46 lakh, and a major revision to the fair value gain on JK Urbanscapes Developers Limited from Rs. 26.27 lakh to Rs. 2,626.57 lakh — a difference of Rs. 2,600.30 lakh. The auditors issued a Qualified Opinion on consolidated results citing: (i) Deferred Tax Assets of Rs. 403 lakh recognised without evidence of future taxable profit in subsidiary Neumesh Labs, and (ii) Rs. 48.60 lakh of revenue expenditure capitalised under CWIP in JK Defence & Aerospace. Profit was understated by Rs. 451.60 lakh due to these issues. Standalone PAT for FY2026 is Rs. 2,783.70 lakh, up sharply from Rs. 1,267.18 lakh in FY2025, largely driven by a Rs. 26,265.71 lakh exceptional fair value gain. Subsidiaries Neumesh Labs and JK Defence have fully eroded net worth but financials are prepared on going concern basis.

Likely market impact

The qualified opinion on consolidated results and unresolved accounting non-compliances in subsidiaries raise concerns about earnings quality and internal controls. The massive revision to exceptional income corrects a significant misstatement. Shareholders should monitor RBI's view on potential NBFC classification and any impairment charges on subsidiary investments.